Literature DB >> 25773118

Cervical cancer: Biomarkers for diagnosis and treatment.

Subramanyam Dasari1, Rajendra Wudayagiri2, Lokanatha Valluru3.   

Abstract

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. With the availability of new technologies researchers have increased their efforts to develop novel biomarkers for early diagnosis, and evaluation and monitoring of therapeutic treatments. This approach will help in the development of early diagnosis and in increasing treatment efficacy with decreased recurrence. The present review explains the currently available biomarkers for cervical cancer diagnosis and prognosis. Apart from the currently available biomarkers the review also explains strategies for the development of biomarkers based on cellular and molecular approaches such as DNA, protein and other metabolic markers with suitable clinical examples. The investigations of specific proteins, enzymes and metabolites will establish more useful biomarkers for accurate detection and management of gynecological cancers especially cervical cancer.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cancer antigen; Cervical cancer; Diagnosis; Magnetic resonance imaging; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 25773118     DOI: 10.1016/j.cca.2015.03.005

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  47 in total

1.  miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.

Authors:  Dongmei Yang; Qiumei Zhang
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

2.  miR-346 Up-regulates Argonaute 2 (AGO2) Protein Expression to Augment the Activity of Other MicroRNAs (miRNAs) and Contributes to Cervical Cancer Cell Malignancy.

Authors:  Junfei Guo; Jing Lv; Min Liu; Hua Tang
Journal:  J Biol Chem       Date:  2015-10-30       Impact factor: 5.157

3.  ALEX1 may be a novel biomarker for human cervical squamous cell carcinoma.

Authors:  Fan Zeng; Kui Liao; Jiayan Wu; Yue Gao; Haiyu Li; Jianjun Fan; Hantao Zhang; Yun Li; Xin Bai; Geili Liu; Fangzhou Song
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  [Cervical cancer : Update on morphology].

Authors:  L-C Horn; C E Brambs; R Handzel; S Lax; I Sändig; D Schmidt; K Schierle
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

5.  Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer.

Authors:  Doo Byung Chay; Gwan Hee Han; Sanghee Nam; Hanbyoul Cho; Joon-Yong Chung; Stephen M Hewitt
Journal:  Int J Clin Oncol       Date:  2019-07-13       Impact factor: 3.402

6.  Comprehensive analysis of novel prognosis-related proteomic signature effectively improve risk stratification and precision treatment for patients with cervical cancer.

Authors:  Xiaoyu Ji; Guangdi Chu; Yulong Chen; Jinwen Jiao; Teng Lv; Qin Yao
Journal:  Arch Gynecol Obstet       Date:  2022-06-17       Impact factor: 2.344

Review 7.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

Review 8.  Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.

Authors:  Rosa Catarino; Patrick Petignat; Gabriel Dongui; Pierre Vassilakos
Journal:  World J Clin Oncol       Date:  2015-12-10

9.  Clinical important dysregulation of long non-coding RNA CCHE1 and HULC in carcinogenesis of cervical cancer.

Authors:  Neda Naghashi; Saeid Ghorbian
Journal:  Mol Biol Rep       Date:  2019-07-30       Impact factor: 2.316

10.  Genetic and Epigenetic Variations of HPV52 in Cervical Precancer.

Authors:  Katharine J Bee; Ana Gradissimo; Zigui Chen; Ariana Harari; Mark Schiffman; Tina Raine-Bennett; Philip E Castle; Megan Clarke; Nicolas Wentzensen; Robert D Burk
Journal:  Int J Mol Sci       Date:  2021-06-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.